Project Grant R01CA301423
- Federal Grant Award Summary The National Cancer Institute awarded a $141,195 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The University of Texas MD Anderson Cancer Center on May 15, 2026, with completion expected by April 30, 2028. This award supports a Pathway to Independence (K99/R00) career development research project investigating how tumor suppressor gene (TSG) deficiencies modulate pancreatic ductal adenocarcinoma (PDAC) response to oncogenic KRAS...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $420,400 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2027. This award supports exploratory studies investigating cellular resistance mechanisms to second-generation MTA-cooperative PRMT5 inhibitors (MTA:PRMT5I) in MTAP-loss tumors. The research addresses a critical clinical challenge whereby 40-60% of patients...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Grant Award Summary The National Cancer Institute awarded a $150,404 Project Grant to The University of Texas MD Anderson Cancer Center, effective December 1, 2025, through May 31, 2028, under the Cancer Research Manpower program (CFDA 93.398). This award supports a research project titled "Dissecting the Role of Gut Microbiome Dysbiosis in Lung Cancer Development and Progression," which investigates the mechanistic relationship between gut microbiome composition and lung...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $688,073 to The University of Texas MD Anderson Cancer Center on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year project through May 31, 2031. Under the direction of Principal Investigator Dr. Peter Van Loo, this project will develop novel computational approaches to reconstruct the evolutionary history of cancer metastases. The research leverages DNA sequencing and molecular...
- Federal Grant Award Summary The University of Texas MD Anderson Cancer Center received a $163,500 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) on July 2, 2025, with completion scheduled for June 30, 2027. This award supports research aimed at developing targeted therapeutic approaches for E-cadherin-negative diffuse-type gastric adenocarcinoma (DGAC), an aggressive cancer subtype with increasing incidence rates and poor...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $131,933 project grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) effective May 1, 2026, through April 30, 2028. The award supports research training and biomedical workforce development in cancer research aligned with the National Cancer Program's strategic priorities. This project grant provides funding for institutional training infrastructure...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Grant Award Summary The National Cancer Institute awarded a $388,546 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Texas Health Science Center at Houston, effective June 1, 2026 through May 31, 2031. This five-year research project investigates the Golgi secretory pathway in chromosome 3q-amplified non-small cell lung cancer (NSCLC), with the goal of developing targeted therapeutic approaches for NSCLC cases lacking actionable mutations in...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $621,632 project grant effective June 17, 2026, through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This award funds research to elucidate the molecular and metabolic mechanisms underlying disulfidptosis, a previously unexplored form of regulated cell death induced by disulfide stress in SLC7A11-high cancer cells. The research...
The University of Texas MD Anderson Cancer Center received a $669,540 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective July 1, 2026 through June 30, 2031. This five-year research initiative investigates the role of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy in KRAS-mutant lung adenocarcinomas (KM-LUADs). The research builds on preliminary findings demonstrating that CD24 is elevated in premalignant and malignant lung cells and functions as a hub for tumor-to-immune cell interactions. The project delivers fundamental cancer biology research aimed at understanding mechanisms that promote KM-LUAD oncogenesis and therapeutic resistance, with the ultimate objective of improving early treatment strategies for patients with KRAS-mutant lung adenocarcinoma. The research products generated through this award include scientific investigations examining CD24 signaling in early lung cancer development and its contribution to immune escape mechanisms, mechanistic studies of how CD24 upregulation occurs following KRAS-targeted inhibition, and translational findings evaluating combination therapeutic approaches targeting both CD24 and KRAS pathways. The work utilizes tobacco carcinogen-exposed mouse models and advanced immunological characterization methodologies to assess tumor progenitor abundance and anti-tumor immune responses, with findings expected to inform development of augmented therapeutic strategies that enhance efficacy of KRAS inhibition in clinical populations.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $669.5k | 6/16/26 |